Colorectal cancer's stubborn resistance to immunotherapy has long been traced to its immunosuppressive tumor microenvironment — a cellular ecosystem dominated by pro-tumor macrophages that actively dampen immune surveillance. A new compound designed to selectively reprogram those macrophages at the metabolic level could shift that equation significantly, with implications for one of the most treatment-resistant solid tumors.
Researchers engineered WGF-T17 (T17), a conjugate molecule that links the glutamine antagonist DON to artesunate, a compound with established macrophage-targeting properties. The design achieves something prior glutamine-blocking agents like DON and its prodrug JHU-083 could not: preferential metabolic disruption within tumor-associated macrophages rather than broad systemic inhibition. In cell studies, T17 forced macrophages away from glutamine-fueled oxidative metabolism and toward glycolysis, producing lactate accumulation that drove histone lactylation — an epigenetic modification associated with pro-inflammatory gene expression. These metabolically reprogrammed macrophages also exhibited enhanced mitochondrial fission and increased phagocytic activity, hallmarks of an anti-tumor M1-like phenotype. In female mice bearing subcutaneous colorectal tumors, T17 outperformed JHU-083 in controlling tumor growth through macrophage-dependent mechanisms, and it amplified the efficacy of immunotherapy, chemotherapy, and anti-angiogenic agents when used in combination.
The metabolic-epigenetic axis uncovered here — glutamine blockade triggering lactate-driven histone modification — adds nuance to the growing field of immunometabolism, which has increasingly recognized that rewiring cellular fuel use can fundamentally alter immune cell identity. The histone lactylation link is particularly notable; it connects metabolic state directly to gene regulation in a way that may be durable rather than transient. That said, several limitations temper enthusiasm: this is preclinical mouse data using subcutaneous tumor models, which are known to poorly recapitulate the complex stromal architecture of human colorectal cancer. The study also focused exclusively on female mice, introducing uncertainty about sex-based generalizability. Toxicity profiling in humans remains entirely uncharacterized. This work is incremental but mechanistically rich — a meaningful step toward precision immunometabolic therapy rather than a clinical breakthrough.